Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis presenting primarily with pulmonary and cutaneous features. The disease is typically seen in the fifth or sixth decade of life (1, 2). We report a case of EGPA in an adolescent who was successfully treated with the interleukin-5 (IL-5) receptor inhibitor, benralizumab.

• Authors: M Bandla, M Howard, A McNally, D Armstrong, I Simpson, A Mar
• Journal: The Australasian journal of dermatology (Australas J Dermatol) Vol. 64 Issue 3 Pg. 404-407 (Aug 2023) ISSN: 1440-0960 [Electronic] Australia
• PMID: 37195732 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2023 Australasian College of Dermatologists.

Chemical References

• benralizumab
• Antibodies, Monoclonal, Humanized

Topics

• Adolescent
• Humans
• Child
• Granulomatosis with Polyangiitis (drug therapy)
• Churg-Strauss Syndrome (drug therapy)
• Antibodies, Monoclonal, Humanized (therapeutic use)